Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endo Unit Shutdown Could Strand Incontinence Treatment Praised By FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Endo International plans to shutter its Astora Women's Health business unit – formerly part of American Medical Systems – this month due to ongoing legal concerns tied to the company’s vaginal mesh products. What’s unclear is what this means for the company’s investigational fecal incontinence treatment, which received unanimous support from an FDA advisory panel just days before the shutdown was announced.

You may also be interested in...

AMS: Pelvic Mesh Plaintiffs Enticed

Some plaintiffs in ongoing multi-district litigation against pelvic mesh manufacturer American Medical Systems were recruited to the case by cold-callers and did not need to have the mesh removed, the company argued in a recent court filing.

TOPAS Fecal Incontinence Device Gets Unanimous Support For Approval At FDA Panel

All members of the agency's Gastroenterology and Urology Devices Panel were convinced by Astora Women’s Health's evidence in support of PMA approval for the TOPAS mesh implant device for fecal incontinence.

PMA Mandate Set For Pelvic Organ Prolapse Transvaginal Mesh

FDA issued final orders up-classifying surgical mesh for transvaginal repair of pelvic organ prolapse from class II to class III and calling for PMA standards, including clinical trial, animal studies, and materials testing data from new and existing manufacturers.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts